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Since itwas first cloned by Caterina et al. (1997), the transient recep-
tor potential (TRP) vanilloid-1 (V1) channel, formerly known as either
the capsaicin receptor or VR1, has remained in the focus of pain research
and drug development (Kaneko & Szallasi, 2014). Interestingly, the ef-
fects of pharmacological inactivation of this channel were studied
since the 1950s (Jancso & Santha, 2015; Szolcsanyi, 2015). At that
time, high doses of capsaicin (CAP), a pungent constituent of chili pep-
pers (genus Capsicum), were shown to desensitize a subset of sensory
nerves with consequent effects on many physiological functions. CAP
is a TRPV1 agonist, and the term desensitization refers to the state of a
decreased neuronal sensitivity to stimuli that normally activate
TRPV1-expressing neurons, e.g., noxious heat (for review, see Holzer,
1991; Szallasi & Blumberg, 1999). Studies of the desensitizing effects
of CAP and other vanilloids, e.g., resiniferatoxin [(RTX), an ultrapotent
TRPV1 agonist naturally found in plants of the genus Euphorbia
(Szallasi & Blumberg, 1989)], paved the way for using TRPV1 agonists
to treat pain (Craft & Porreca, 1992; Szallasi & Blumberg, 1999). For ex-
ample, epidermal Qutenza (CAP-containing patch) was developed for
treating neuropathic pain, while intrathecal RTX has been proposed
for treating pain in some forms of cancer (Chung & Campbell, 2016;
Moran & Szallasi, 2018). In the late 1990s, while continuing to work
on analgesic treatments based on the desensitizing property of TRPV1
agonists, multiple pharmaceutical companies had started developing
TRPV1 antagonists (Holzer, 2008; Kyle & Tafesse, 2006; Lee et al.,
2015). (Throughout this review, we use the terms “antagonist” and
“blocker” interchangeably.) Highly potent and selective TRPV1 antago-
nists were, and perhaps still are, hoped to usher in a new generation
of non-opioid analgesics. However, during the in-vivo testing of TRPV1
antagonists, adverse effects on body temperature (Tb), primarily hyper-
thermia, were repeatedly observed in animal studies and human clinical
trials alike (vide infra). This review examines the thermal effects of
TRPV1 antagonists and reports the results of a mathematical-modeling
analysis and meta-analysis of Tb data from human trials.
In addition to vanilloids, many other stimuli are known to
activate (open) the TRPV1 channel (Jordt, Tominaga, & Julius,
2000). Traditionally, when studying the TRPV1-antagonizing prop-
erty of compounds, pharmaceutical companies use the following
stimuli to activate this channel: CAP, low extracellular pH (b 6),
and sometimes heat (N 42°C) (Fig. 1). Hence, in this review, we dis-
cuss three modes of TRPV1 activation: CAP, proton, and heat, respec-
tively. It is now known that TRPV1 antagonists can affect these three
modes differentially (for review, see Blumberg, Pearce, & Lee, 2011;
Romanovsky et al., 2009). For example, a compound can potently
block TRPV1 activation by CAP, but potentiate TRPV1 activation by
protons (Garami, Pakai, et al., 2018; Lehto et al., 2008). In the present
work, we attempted to determine the activation-mode profiles of
TRPV1 antagonists that induce hyperthermia, have no effect on Tb,
or even cause hypothermia in humans. Based on the results of our
analyses, presented herein, we examine the strategies of minimizing
the thermoregulatory effects of TRPV1 antagonists, but also of using
these effects for therapeutic purposes, in humans.2. The hyperthermic effect of TRPV1 antagonists in laboratory
animals
2.1. Phenomenology
Upon systemic administration, whether intravenous (i.v.), intraper-
itoneal (i.p.), or peroral (p.o.), many TRPV1 antagonists cause hyper-
thermia in a variety of laboratory animal species, including the mouse,
rat, guinea pig, dog, and cynomolgus monkey (Macaca fascicularis)
(Fig. 2). This hyperthermia appears to be independent of chemical
structure. It has been shown to develop in response to small-molecule
TRPV1 antagonists belonging to different chemotypes, viz., cinnamides
(AMG0347 and AMG9810), pyrimidines (AMG 517), ureas (JYL 1421
and A-425619), and piperazines (BCTC), thus suggesting an on-target
action (for review, see Romanovsky et al., 2009). Indeed, the on-target
nature of the hyperthermic effect of TRPV1 antagonists was determined
definitively, when Steiner et al. (2007) and Garami et al. (2011, 2010)
showed that TRPV1 knockoutmice did not increase Tb in response to ei-
ther AMG0347 or AMG 517, whereas wild-type mice responded to ei-
ther compound with hyperthermia.
However, not all TRPV1 antagonists are made equal as far as their
ability to cause hyperthermia. While most TRPV1 antagonists produce
the hyperthermic response at systemic doses in the mg/kg range
(Gavva, Bannon, Surapaneni, et al., 2007; Swanson et al., 2005), others
(e.g., AMG0347) are effective already at 10 μg/kg (Gavva et al., 2008;
Steiner et al., 2007), and yet others (e.g., AS1928370) do not seem to af-
fect Tb at all (Watabiki, Kiso, Kuramochi, et al., 2011). Some TRPV1 an-
tagonists have been shown to be hyperthermic in several mammalian
species, whereas others cause hyperthermia only in particular species.
For example, AMG0347 and AMG 517 increase Tb in both rats and
mice (Garami et al., 2010; Steiner et al., 2007), whereas capsazepine
(CPZ) increases Tb in guinea pigs but has no thermal effect in rats
(Garami et al., 2010). Intriguingly, some TRPV1 antagonists (e.g., A-
1165901, A-425619, AMG7905, and AMG8562) cause hypothermia in-
stead of hyperthermia (Garami, Pakai, et al., 2018; Lehto et al., 2008;
Mills et al., 2008). And yet other compounds appear to affect Tb regula-
tion in a species-specific fashion, e.g., JYL1421 was shown to cause hy-
perthermia in dogs and cynomolgus monkeys [Fig. 2D and E; also see
Gavva, Bannon, Surapaneni et al. (2007)] but hypothermia in rats
[Fig. 3D; also see Garami et al. (2010)]. Similar to the hyperthermic ef-
fect, the hypothermic effect of TRPV1 antagonists is also independent
of the chemotype, as hypothermia occurs in response to small mole-
cules with diverse chemical structures, e.g., A-1165901, AMG7905,
JYL1421 (Fig. 3), or AbbVie’s Compound 3 (Gomtsyan et al., 2015).
Two polypeptide TRPV1 antagonists, APHC1 and APHC3, have also
been reported to cause hypothermia in rats (Andreev et al., 2013). In
agreement with this, the hypothermic effect of TRPV1 antagonists is ab-
sent in TRPV1 knockout mice (Garami, Pakai, et al., 2018). Hence, both
the hyper- and hypothermic effects of TRPV1 antagonists occur by act-
ing on the same receptor, TRPV1, which is a highly unusual scenario.
When a compound causes two opposite responses, these responses
are typically mediated by different receptors (Garami, Pakai, et al.,
2018). This paradox of a dual thermoregulatory action mediated by
Fig. 1. TRPV1 activation: a schematic. Upon stimulation by CAP, protons, or heat, the TRPV1 channel opens, and Na+ and Ca2+ cations from the extracellular space enter the cell.
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effects of TRPV1 antagonists have several other surprising physiological
features.
2.2. Physiological mechanisms
Those TRPV1 antagonists that induce hyperthermia do so (at least in
rats) by recruiting autonomic cold-defense effectors, i.e., triggering tail-
skin vasoconstriction and activating nonshivering thermogenesis in
brown adipose tissue (Garami et al., 2010; Steiner et al., 2007). The
same thermoeffectors – but working in reverse – bring about the hypo-
thermic response to TRPV1 antagonists, when it occurs. In the latter
case, tail-skin vasoconstriction is replaced by vasodilation, while ther-
mogenesis is suppressed (Garami, Pakai, et al., 2018). Because the
TRPV1 channel is highly sensitive to temperature (for review, see
Zheng&Wen, 2019), it is often assumed that temperature signals trans-
mitted by TRPV1 drive effector responses of the thermoregulation sys-
tem, or, in other words, that the TRPV1 channel serves as aFig. 2.Hyperthermic responses to TRPV1 antagonists in laboratory mammals. A) Effect of AMG0
temperature (Ta) of 31°C. B) Effect of AMG517 (100 μg/kg, i.v.) or its vehicle on colonic temperat
on abdominal temperature of guinea pigs at a neutral Ta of 27°C. D) Effect of JYL1421 (30mg/kg
JYL1421 (30mg/kg, p.o.) or its vehicle on Tb (location not specified) in cynomolgusmonkeys at r
Gavva et al. (2008) (B); modified from Garami et al. (2010) (C) and Gavva, Bannon, Surapanenthermosensor for the thermoregulation system. Accordingly, it is fur-
ther assumed that the thermoregulatory effects of TRPV1 antagonists
are due to the blockade of the channel’s thermosensory function
(McGaraughty et al., 2009; Seebacher et al., 2010; Szolcsanyi, 2015;
Vriens, Nilius, & Voets, 2014). This, however, appeared not to be the
case (Romanovsky et al., 2009).
If the activity of thermoeffectors (and, consequently, the deep Tb)
were to depend on TRPV1-mediated thermal signals, the magnitude of
the hyperthermic effect of TRPV1 antagonists would depend on tissue
temperatures in different areas of the body – deep (if the sensors are lo-
cated inside the body), superficial (if the sensors are in the skin), or
both. High Tbs represent strong warmth signals (that inhibit cold de-
fenses, activate heat defenses, and – through a negative feedback loop
– suppress Tb); under such conditions, TRPV1 antagonists would re-
move this Tb suppression and be expected to bring about a strong hy-
perthermic effect. Low Tbs are equivalent to the lack of warmth signals
affecting thermoregulation; under such conditions, the removal of the
nonexistent warmth signals by TRPV1 antagonists would be expected347 (500 μg/kg, i.p.) or its vehicle on abdominal temperature inmice at a neutral ambient
ure in rats at a neutral Ta of 26°C. C) Effect of capsazepine (CPZ; 25mg/kg, i.v.) or its vehicle
, p.o.) or its vehicle on Tb (location not specified) in dogs at room temperature. E) Effect of
oom temperature.Modified from Steiner et al. (2007) (A);modifiedwith permission from
i, et al. (2007) (D, E).
Fig. 3.Hypothermic responses to different TRPV1 antagonists in rats andmice. A) Effect of
A-1165901 (10 mg/kg, i.p.) or its vehicle on abdominal temperature in mice at a
subneutral Ta of 20°C. B) Effect of AMG7905 (10 mg/kg, i.p.) or its vehicle on abdominal
temperature in mice at a subneutral Ta of 20°C. C) Effect of A-1165901 (3 mg/kg, i.p.) or
its vehicle on colonic temperature in rats at a Ta of 26°C (the low end of the
thermoneutral zone). D) Effect of JYL1421 (111 mg/kg, i.p.) or its vehicle on colonic
temperature in rats at a Ta of 26°C (the low end of the thermoneutral zone). Graphs are
reprinted from Garami, Pakai, et al. (2018) (A, B, C) or plotted for this work using data
from Garami et al. (2010) (D).
Fig. 4. In rats, the magnitude of the hyperthermic response to a TRPV1 antagonist is
independent of both the initial (at the time of drug administration) colonic temperature
or initial tail-skin temperature in a wide range of temperatures. A) AMG0347 (50 μg/kg,
i.v.) was injected in rats at a Ta of 17, 24, or 28°C. At all Ta values tested, the drug
induced hyperthermic responses of similar magnitude. No positive correlation was
found when the response magnitude (the maximal increase in colonic temperature) for
each rat was plotted either against the initial colonic temperature (B) or against the
initial tail-skin temperature (C). Reprinted with permission from Romanovsky et al.
(2009); the figure uses data from Steiner et al. (2007).
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to be true for the cold-sensitive TRP channel melastatin-8 (TRPM8).
TRPM8 antagonists cause hypothermia in rats (Almeida et al., 2012;
deOliveira et al., 2014), and themagnitude of thehypothermic response
increases with a decrease in the ambient temperature (Ta) and Tbs, in-
cluding skin temperatures – when the thermal (i.e., cold) activation of
TRPM8 is stronger, the blockade of this activation with an antagonist
causes a stronger Tb response (Almeida et al., 2012). Hence, TRPM8 is
a physiologically important temperature sensor that drives
thermoeffector responses in the rat.
For the TRPV1 channel, the assumptions described above turned out
to be incorrect, at least in the case of young male rats. Steiner et al.
(2007) have analyzed whether the extent of hyperthermia depends
on the initial (preinjection) temperatures (deep Tb, tail-skin tempera-
ture, and Ta) in response to an i.v. injection of the potent TRPV1 antag-
onist AMG0347. The authors found no positive correlation between
the magnitude of the hyperthermia and any of the initial temperatures
measured (Fig. 4). The lack of a positive correlation indicates that the
tonic activation of TRPV1 channels, which maintains the tonic suppres-
sion of Tb, is nonthermal in nature.A priori, such nonthermal factorsmay
include a low pH, inorganic cations, or endovanilloids. The fact that
TRPV1 activation by heat plays no role in the thermoregulatory effects
of TRPV1 antagonists (or in thermoregulation in general), at least in
male rats, was confirmed in later studies [for more detail, see section
2.4 and Garami et al. (2010), Garami, Pakai, et al. (2018), Lehto et al.
(2008)].
The highest levels of TRPV1 expression are found in the primary sen-
sory neurons of dorsal-root and trigeminal ganglia, both in rodents(Jang et al., 2012; Sanchez, Krause, & Cortright, 2001) and in humans
(Cortright et al., 2001). However, TRPV1 channels arewidely distributed
throughout the body and expressed abundantly on neural elements
both within and outside of the central nervous system; they are also
found in non-neural tissues (reviewed by Romanovsky et al., 2009).
Where are the TRPV1 channels that mediate the Tb effects of nonther-
mal tonic stimuli (and, consequently, the thermoregulatory effects
of TRPV1 antagonists) located? To answer this question, Steiner
Fig. 5. The hyperthermic response to TRPV1 antagonists does not occur in rats with
localized intra-abdominal TRPV1 desensitization. Shown is the abolished hyperthermic
effect of AMG0347 (50 μg/kg, i.v.) in rats pretreated with RTX (20 μg/kg, i.p.). Reprinted
with permission from Romanovsky et al. (2009); the figure uses data from Steiner et al.
(2007).
Table 1
Sites of TRPV1 desensitization in RTX- or vehicle-pretreated rats
Pre-treatment Compartment Desensitization pattern Desensitization extent
Abdominal cavity Eyes Skin Thoracic cavity Brain
Vehicle 0 0 0 0 0 None
RTX 0.2 mg/kg i.p. X X X X X Systemic
RTX 0.02 mg/kg i.p. X 0 0 0 0 Localized intra-abdominal
The state of TRPV1 channels in different bodily compartments ismarkedas follows: X, desensitized; 0, non-desensitized. In schematics of the desensitization pattern, the desensitized com-
partments are shown in grey; the non-desensitized compartments are shown in white. Reprinted with permission from Romanovsky et al. (2009); the table was built based on the data
reported by Steiner et al. (2007).
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administered directly into the central nervous system (viz.,
intracerebroventricularly or intrathecally) and systematically (i.v.). If a
central administration were to cause hyperthermia at much lower
(10-100 times) doses than a peripheral administration, this would indi-
cate a central action. This, however, was not the case. The authors found
that the threshold hyperthermic dose of AMG0347, when administered
i.v., was ~6 μg/kg (a significant effectwas observed at 10 μg/kg), but that
the drug did not cause any changes in Tb when the dose of 6 μg/kg was
administered centrally (either intracerebroventricularly or intrathe-
cally). These findings allowed the authors to exclude a central origin
of the hyperthermic response to AMG0347.
To obtain a more precise location of the channels responsible for the
hyperthermic effect of TRPV1 antagonists, Steiner et al. (2007) adminis-
tered AMG0347 i.v. in rats that had TRPV1 channels desensitized in dif-
ferent compartments of the body. As explained above (Introduction),
desensitization means a decreased neuronal sensitivity to exogenous
or endogenous vanilloids or other stimuli that normally activate
TRPV1-expressing neurons, e.g., noxious heat (Craft & Porreca, 1992;
Szallasi & Blumberg, 1999). Steiner et al. (2007) administered repeated,
escalating i.p. doses of RTX to rats to achieve different desensitization
patterns (Table 1). At higher doses (~200 μg/kg), RTX impairs the func-
tion of TRPV1 channels throughout the entire body (systemic desensiti-
zation).When lower doses are used (~20 μg/kg), the desensitizing effect
is limited to the abdominal cavity (localized, intra-abdominal desensiti-
zation). In the latter case, TRPV1-mediated reflexes triggered from the
abdominal cavity (e.g., RTX-induced writhing) are suppressed, while
TRPV1 sensitivity in all other body compartments remains intact
(Table 1). It was found that the hyperthermic response to either
AMG0347 [Fig. 5; also see Steiner et al. (2007)] or another TRPV1 antag-
onist, A-889425 (McGaraughty et al., 2009), was absent in rats with lo-
calized, intra-abdominal desensitization.More recently, we have shown
that the hypothermic effect of the TRPV1 antagonist A-1165901 is also
abolished following the intra-abdominal TRPV1 desensitization in rats
(Garami, Pakai, et al., 2018). The results in RTX-desensitized rats show
that both the hyper- and hypothermic responses to TRPV1 antagonists
are triggered from the abdomen, perhaps the intra-abdominal viscera
or abdominal-wall muscles (for further discussion, see Garami, Pakai,
et al., 2018).
To summarize this section, the following picture has emerged.
TRPV1 antagonists produce their thermoregulatory effects by acting
on TRPV1 channels located somewhere in the abdomen: in the abdom-
inal viscera or abdominal-wall muscles. The abdominal TRPV1 channels
are tonically activated by some nonthermal stimuli. The most common
thermoregulatory effect of TRPV1 antagonists – hyperthermia – results
from the blockade of this nonthermal TRPV1 activation and, conse-
quently, from disinhibition of cold defenses. What stimuli tonically acti-
vate the abdominal TRPV1 channels under normal conditions? Why
would thermoregulatory responses be triggered by nonthermal,
TRPV1-mediated stimuli from the trunk? Before we answer thesequestions, we will take a more careful look at different ways to activate
the TRPV1 channel.
2.3. Mode selectivity of TRPV1 activation and differential TRPV1
pharmacology
Rat (r) TRPV1 is the most studied TRPV1 ortholog, for which six
cryo-electron microscopy structures with a resolution varying from
3.0 to 4.2 Å have been obtained, thus providing direct insight into the
polymodal regulation of this channel (Cao, Liao, Cheng, & Julius, 2013;
Gao, Cao, Julius, & Cheng, 2016; Liao, Cao, Julius, & Cheng, 2013). De-
rived from the structural biology studies, the molecular architecture of
TRPV1 shows that the channel is a tetramer with six transmembrane
helices (S1-S6). The transmembrane domain is further divided into
two structural (sub-)domains: the voltage-sensing-like (sub-)domain
(helices S1-S4) and the pore (sub-)domain (S5-S6), as illustrated in
Fig. 6. The pore domain houses the upper and lower gates that open
and close in response to diverse stimuli, including CAP, protons, and
heat (Yang et al., 2018).
The combined data from a variety of methods paint the clearest pic-
ture of themolecularmechanisms associatedwith rTRPV1 activation by
CAP and related vanilloid compounds (Yang & Zheng, 2017). Early com-
parative studies of TRPV1 orthologs with different CAP sensitivity iden-
tified the vanilloid-binding pocket, of which there are four per a
Fig. 6.Molecular architecture of TRPV1. A) A color-coded schematic of a TRPV1monomer
shows the voltage-sensing-like subdomain (S1-S4; red) and the pore subdomain (S5-S6;
purple) of the transmembranedomain, aswell as the S4-S5 helix linker (cyan) and the TRP
helix (orange). The intracellular N- and C-termini include a series of six ankyrin-repeat
domains and a C-terminal domain, respectively. The so-called selectivity filter of TRPV1
is formed from the loop that links the pore helix with the S6-helix. B) The tetrameric
structure of TRPV1 (pdb ID: 3J5P) is shown with the same color-coding. The pore
subdomain (purple), in its tetrameric form, includes the upper and lower gates that
regulate channel activation. C) An extracellular view of the TRPV1 structure shows how
the tetrameric pore subdomain forms an ion-conductive pathway (pore), which is
regulated by CAP, protons, and heat.
Fig. 7. Activation of TRPV1 by distinct stimuli. TRPV1 is activated by a variety of diverse
stimuli, including protons, CAP, and heat, via spatially distinct mechanisms. A) The
canonical vanilloid agonist CAP binds to the voltage-sensing-like membrane subdomain
in the intracellular leaflet. B) The proton-sensing mechanism is localized primarily on
the extracellular loops of the TRPV1 pore subdomain. C) The heat-activation mechanism
is not well-understood. The current data suggest that the core heat-sensing architecture
is harbored by the transmembrane region.
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vanilloid-binding pocket (Fig. 7A) was further validated by functional,
computational, and structural studies (Cao, Liao, et al., 2013; Yang
et al., 2015). Activation of TRPV1 by CAP is initiated at the intracellular
side of the membrane, where CAP binds to the voltage-sensing-like do-
main within the pocket. The vanilloid-binding pocket is energetically
coupled with the pore domain, and CAP binding causes the lower gate
at the S6 helix bundle crossing to open, followed by further conforma-
tional rearrangements and coupling that are propagated to the selectiv-
ity filter on the extracellular side of themembrane (i.e., the upper gate),
resulting in channel activation (Yang et al., 2018). While TRPV1 is theonly TRPV family member that is inherently activated by vanilloids,
themechanismic understanding of TRPV1proved to be sufficient for en-
gineering vanilloid sensitivity into the TRPV2 and TRPV3 channels
(Yang, Vu, Yarov-Yarovoy, & Zheng, 2016; Zhang et al., 2016), hence fur-
ther validating the proposed model of CAP sensitivity.
Proton activation of rTRPV1 is also relatively well-studied
(Boukalova, Teisinger, & Vlachova, 2013; Jordt et al., 2000). The key re-
gions that impart proton sensitivity are located in the extracellular loops
of the pore domain, across the membrane from the vanilloid-binding
pocket (Fig. 7B). Canonically, two glutamate residues (E600 and E648)
function as putative proton sensors, where the magnitude and range
of TRPV1 pH sensitivity depend on the chemical nature of these side
chains. Proton activation is initiated in the extracellular pore domain
loops and then propagated to the pore helix and the upper gate (Ryu,
Liu, Yao, Fu, & Qin, 2007). From there, the activation is spread to the
lower gate, thus resulting in proton-dependent channel opening, i.e.,
gating. Given the distinct spatial origins of CAP (vanilloid) and proton
activation, it is interesting to note that othermodes of TRPV1 regulation
and activation are thought to occur extracellularly, with overlapping
mechanisms to proton activation (Bohlen et al., 2010; Cao, Liao, et al.,
2013; Jara-Oseguera, Bae, & Swartz, 2016). Specifically, a sodium-
binding site is known to stabilize the rTRPV1 closed state in this region
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double-knot toxin) activates TRPV1 in the pore domain extracellular
loops (Bohlen et al., 2010).
The mechanism of heat activation of rTRPV1 is still debated, as is the
exact location of where heat is sensed within the channel, or even if a
discreet “heat-sensor” location exists at all (Voets et al., 2004; Zheng &
Wen, 2019). Indeed, virtually all areas of TRPV1 have, at one point or an-
other, been ascribed some participation in heat activation (Hilton, Rath,
Helsell, Beckstein, & Van Horn, 2015; Voets, 2014). Nonetheless, it is
clear that thermosensitivity is an inherent feature of TRPV1 (Cao,
Cordero-Morales, Liu, Qin, & Julius, 2013). Based on the current litera-
ture, the transmembrane region is emerging as central to
thermosensitivity (Hilton, Kim, & Van Horn, 2019; also see Fig. 7C). Re-
cent studies have shown that the pore domain of rTRPV1 is sufficient to
endow a non-thermosensitive channel with heat activation, indicating
that this domain is crucial for thermosensitivity (Zhang et al., 2018).
There is also recent evidence that the human (h) TRPV1 voltage-
sensing-like domain contributes to thermosensitivity (Kim et al.,
2019). This domain undergoes a temperature-dependent conforma-
tional change that has been implicated in channel activation through
the S4 helix to the pore domain, with some similarities to the mecha-
nism of vanilloid activation. While there is strong evidence for
species-specific phenotypes in TRPV1 and other TRP channels (Garcia-
Avila & Islas, 2019; Hilton et al., 2015), the available data suggest that
the transmembrane domain is central to heat activation, with
extramembrane domains potentially modulating thermal responses.
For the TRP ankyrin-1 (TRPA1) channel, a distinct thermosensitive
channel, which shares the transmembrane architecture and ankyrin-
repeat-based intracellular domain structures with TRPV1 (Saito &
Tominaga, 2017), the temperature-sensitive region has been narrowed
down to the transmembrane and C-terminal regions (Moparthi et al.,
2014). More recently, temperature sensing in the TRPV3 channel has
also been localized to the transmembrane domain (Singh, McGoldrick,
& Sobolevsky, 2018).
Species differences, especially between rTRPV1 and hTRPV1, deserve
a separate discussion. Given that the two orthologs originate from a
common evolutionary ancestor and share ~85% sequence identity, as
well as most general structural features, including the conserved trans-
membrane domain, they are expected to function similarly (Hilton
et al., 2019). Indeed, the concentration of CAP that produces a half-
maximal response in vitro is similar for the two channels (McIntyre
et al., 2001), and they also have similar heat activation thresholds
(McIntyre et al., 2001) and thermosensitivities (Kim et al., 2019). How-
ever, the sensitivity to protons differs between the two channels. In
vitro, the half-maximal response occurs at the pH of ~5.8 in rTRPV1
but at the pH of ~5.5 in hTRPV1 (McIntyre et al., 2001), with the differ-
ence between the two pH values (~0.3) being very large from the phys-
iological point of view. Hence, rTRPV1 is substantially more sensitive to
protons than hTRPV1.
To summarize, it is clear that TRPV1 activation by diverse mecha-
nisms can be spatially distinct, as evidenced by activation by CAP and
protons. It is important that the spatial separation of different activation
modes of TRPV1 can be exploited pharmacologically. Some TRPV1 an-
tagonists block activation of TRPV1 in all modes (i.e., by CAP, heat, and
protons) with similarly high potency; these antagonists are called
polymodal, mode-nonspecific (or mode-nonselective) and represent
the first generation of TRPV1 antagonists. Examples of the first-
generation blockers include AMG1629, AMG3731, AMG 517,
AMG0347, and ABT-102 (Table 2). Yet other compounds affect TRPV1
activation in different modes differentially; they are called mode-
specific (or mode-selective) and represent the second generation of
TRPV1 antagonists. Second-generation compounds potently block the
CAP and heat activation modes (e.g., AMG2820 and AMG7988) or just
solely the CAP mode (e.g., SB-366791), while not affecting the remain-
ing modes, blocking them with lower potency, or even potentiating
TRPV1 activation in these modes. Examples of compounds thatpotentiate TRPV1 activation by protons include A-1165901, AMG8562,
and JYL1421, while the TRPV1 antagonist AMG7905 potentiates TRPV1
activation by both heat and protons (Table 2). It should be noted, how-
ever, that different scientistsmay assign the same compound to a differ-
ent generation, because the potencies of a TRPV1 antagonist in all three
main activation modes are never identical, and a big difference for one
author may look insignificant to another. It is also important to note
that, to the best of our knowledge, all TRPV1 antagonists block TRPV1
activation by CAP with reasonable potency. This is due to the fact that
pharmaceutical companies, while working on TRPV1 antagonists (at
least at the early stages of their TRPV1 programs), often “discarded”
any molecules that did not block TRPV1 activation by CAP – such com-
poundswould not be considered TRPV1 antagonists. Of interest, accord-
ing to R. Kapil and D. J. Kyle (personal communication), the TRPV1
programat Purdue Pharma, one of the pioneers in thefield of TRPV1 an-
tagonists, never found amolecule that blocked TRPV1 activation by pro-
tons without also blocking CAP activation.
2.4. Modeling: which modes of TRPV1 activation contribute to the hyper-
thermic response in rats?
We now know (Table 2) that TRPV1 antagonists can affect Tb in sev-
eral ways, even in the same species (e.g., the rat): many of them readily
produce hyperthermia (sometimes, they are called “hyperthermic”
compounds); some have no thermal effect at comparable doses (“ther-
mally neutral” compounds); and yet others can cause hypothermia
(“hypothermic” compounds). Can the ability of TRPV1 antagonists to
cause different thermoregulatory responses be ascribed to their differ-
ent effects on different modes of TRPV1 activation? This question was
asked by scientists at Amgen (and later, among others, by scientists at
AbbVie, formerly Abbott Laboratories), who synthesized a variety of
compounds with differential effects on TRPV1 activation in different
modes. Lehto et al. (2008) observed that, in rats, TRPV1 antagonists
that potently blocked channel activation by protons (many examples
are given in Section 2.3 above; also see Table 2) typically caused hyper-
thermia, whereas compounds that potentiated proton activation (e.g.,
AMG8562 and AMG7905) caused hypothermia instead of hyperthermia
(Table 2). However, without an advanced quantitative analysis, it is dif-
ficult to identify with certainty the relationship between the potency of
a compound to block TRPV1 activation in any given mode in vitro and
the effect of this compound on Tb in vivo. This uncertainty is due to,
among other factors, the fact that both the thermoregulatory effect
and the effect on channel activation are dose-dependent. For example,
if a compound does not affect Tb, it can be inherently incapable of affect-
ing it or, alternatively, it might have been used at a subthreshold dose
for the hyperthermic effect. Furthermore, if a compound is amoderately
potent blocker of TRPV1 activation in a certain mode, e.g., by heat, and
causes hyperthermia at moderate doses, it can be interpreted that
blockers of TRPV1 activation by heat cause hyperthermia, even though
the administration of a relatively low dose of this, relatively weak,
blocker of TRPV1 activation by heat, could have resulted in the in-vivo
concentrations that were insufficient to block heat activation. Not sur-
prisingly, therefore, some studies based on comparing thermoregula-
tory effects of a small number of compounds administered at a couple
of doses resulted in unfounded conclusions. For example, at one point,
a conclusion was made that hyperthermic TRPV1 antagonists are
those that block TRPV1 activation by both CAP and heat, regardless of
their effect on proton activation (Gavva, Bannon, Surapaneni, et al.,
2007). This conclusion was then adopted in many reviews and
original-research articles (see, for example, Alawi & Keeble, 2010;
Rawls & Benamar, 2011; Wong & Gavva, 2009). Yet, the subsequent re-
search showed that this conclusion had to be modified (Garami, Pakai,
et al., 2018). Clearly, a comprehensive quantitative analysis was needed.
A quantitative analysis of the contribution of the blockade of differ-
ent activation modes of the TRPV1 channel to the hyperthermic re-
sponse to TRPV1 antagonists was performed by our group (Garami
Table 2
TRPV1 antagonists: Their effects on deep Tb upon systemic administration in rats and their potencies at different activation modes of rat TRPV1 in vitro
8 A. Garami et al. / Pharmacology & Therapeutics 208 (2020) 107474
9A. Garami et al. / Pharmacology & Therapeutics 208 (2020) 107474
10 A. Garami et al. / Pharmacology & Therapeutics 208 (2020) 107474
The effects on deep Tb are marked as follows: ↑, an increase; ↓, a decrease;↔, none.
The range of IC50 values in the three activationmodes is color-coded as follows: 1-9 nM: (CAP), (proton), (heat); 10-99 nM: (CAP), (proton), (heat); 100-999
nM: (CAP), (proton), (heat); N1,000 nM: X (any activation mode). These ranges roughly correspond to the following inhibition potencies: strong, moderate, weak, and
none, respectively. When different potencies are reported for the same compound, they are shown (as different colors) within the same cell. When potentiation occurs instead of
inhibition, the effect is marked as such.
Other notes: ⁎Compound 3 and I-RTX are partial agonists (Gomtsyan et al., 2015; Shimizu et al., 2005); †CAP concentration used in the study of A-889425 byMcGaraughty et al. (2009) and
in the study of CPZ by Phillips, Reeve, Bevan, and McIntyre (2004) was not specified.
11A. Garami et al. / Pharmacology & Therapeutics 208 (2020) 107474et al., 2010).Wedeveloped amathematicalmodel and used it to analyze
a set of data obtained from 49 groups of rats, where each group was
treated with either a distinct dose of a TRPV1 antagonist (eight antago-
nists were used) or vehicle. Of the antagonists studied, seven caused
dose-dependent hyperthermia, whereas one (JYL1421) caused dose-
dependent hypothermia. The analysis revealed that the hyperthermic
response to a TRPV1 antagonist is highly sensitive to changes in the
compound’s in-vitro potency to block TRPV1 activation by protons, but
is completely insensitive to the potency to block either heat or CAP ac-
tivation of the channel (Fig. 8). In other words, only potent antagonists
of proton activation of rTRPV1 cause hyperthermia in young male rats,
and this effect does not depend on the antagonist’s potency to block
othermodes of rTRPV1 activation.We later confirmed that those antag-
onists that potentiate theproton activation of TRPV1 cause hypothermia
(Garami, Pakai, et al., 2018).As explained elsewhere (Garami, Pakai, et al., 2018), the results with
the CAP activation mode were initially not as clear as described in the
paragraph above. In fact, the Garami et al. (2010) model produced
two different outcomes, depending onwhether the hypothermic antag-
onist JYL1421 was included in the analysis or not. The results described
above and shown in Fig. 8 were obtained with a complete data set, i.e.,
with JYL1421. If JYL1421was excluded from the analysis, the hyperther-
mic response to a TRPV1 antagonist became somewhat sensitive to
changes in the antagonist’s potency to block CAP activation of TRPV1 –
in addition to being highly sensitive to changes in the proton mode
and insensitive to changes in the heat mode. At the time when the rat
study (Garami et al., 2010) was conducted, we did not know whether
the hyper- and hypothermic responses to TRPV1 antagonists had two
distinct mechanisms (e.g., one represented an off-target action) or, al-
ternatively, whether they were brought about by the samemechanism,
Fig. 8. Schematic presentation of the mathematical modeling results to show the contribution of different modes of TRPV1 activation to the development of TRPV1 antagonist-induced
hyperthermia in rats. Signals activating TRPV1 in the heat mode (red line), proton mode (blue line), and CAP mode (orange line) are differentially blocked by TRPV1 antagonists (black
lines) to cause the hyperthermic response H (see Supplementary Methods). The k1, k2, and k3 values are relative sensitivities of H to the extent of TRPV1 blockade in the heat, proton,
and CAP modes, respectively. Reprinted from Garami et al. (2010).
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should have been excluded from the analysis; in the latter case, they
should have been included. In a more recent work (Garami, Pakai,
et al., 2018), we studied the hypothermia-inducing TRPV1 antagonists
A-1165901 and AMG7905 and found that the hyper- and hypothermic
responses are similar from the mechanismic point of view. Both repre-
sent an on-target action (do not occur in TRPV1 knockout animals);
both recruit the exact same thermoeffectors (but working in reverse);
both are characterized by the same dependence of thermoeffectors on
Ta; and both depend on the proton mode of TRPV1 activation (potently
block vs. potentiate it). Hence, we concluded that TRPV1 antagonists
cause hypothermia by engaging the same mechanisms as the hyper-
thermic TRPV1 antagonists but in reverse (Garami, Pakai, et al., 2018).
Therefore, our earlier mathematical modeling study (Garami et al.,
2010) should have been interpreted using a complete data set (with
JYL1421), and the results obtained on the complete data set are de-
scribed herein (Fig. 8).
2.5. Putting it all together: “illogical” acidification-induced anti-
hyperthermic reflexes
A concept has emerged (Garami, Pakai, et al., 2018; Romanovsky
et al., 2009) proposing that, at least in young male rats, TRPV1 does
not serve as a thermosensor that drives thermoeffector responses –
even though the thermosensing function of the channel is involved in
pain in this species (Jhaveri, Elmes, Kendall, & Chapman, 2005;
McGaraughty, Chu, Faltynek, & Jarvis, 2006; Vandewauw et al., 2018).
Instead, TRPV1 participates in thermoregulation by sensing protons
(or other stimuli that activate the channel through the samemechanism
as protons). The TRPV1 channels that are tonically activated by protons
and drive thermoeffectors are located somewhere in the abdominal vis-
cera or muscles. TRPV1 antagonists affect thermoregulation, at least in
young male rats, by affecting the activation of these TRPV1 channels.
This picture has been drawn based on the robust experimental support
(reviewed herein and elsewhere). Furthermore, as evident from the
consensus paper (Garami, Pakai, et al., 2018), this view is now accepted
not only by some academic scientists, but also by colleagues from
Amgen and AbbVie – two companies that carried out a great amount
of pioneering work with TRPV1 antagonists. And yet, this picture is
rarely mentioned in the literature, while the alternative view (i.e., that
TRPV1 plays a thermosensory role in mammalian thermoregulation,
and that TRPV1 antagonists affect Tb by blocking thermal activation of
TRPV1) is widely spread. To the best of our knowledge, the thermal na-
ture of the effector-driving TRPV1 signals – the cornerstone of this alter-
native view – has not been demonstrated so far, not even in a single
study. Perhaps the main reason for the slow acceptance of the new re-
flexes, which can be called acido-antithermogenic and acido-antivasoconstrictor, is related to fact that they do not “make sense” at
the first glance. Indeed, what is the biological significance of bringing
the Tb down when the environment in the trunk is acidified?
Those reflexes that seem to make no sense are called “illogical”
(Partridge, 1982; Romanovsky et al., 2009). The autonomic regulation,
including thermoregulation, is executed bymultiple, independent effec-
tor loops using both humoral and neural signals; the latter are called re-
flexes (Romanovsky, 2018). These reflexes are quite diverse, and only a
small subset of them is active under any given set of external and inter-
nal conditions;when conditions change, a different subset of loops is re-
cruited. We readily understand those reflexes that are vital, often
engaged in everyday life of the organism, and well-studied, e.g., various
baroreflexes used in the cardiovascular control. Such reflexes seem “log-
ical”. Yet, there are many other reflexes that we do not understand, and
some thermoregulatory reflexes that are triggered by nonthermal stim-
uli belong to this group. For example, skin vasoconstriction is affected by
colorectal distension (Laird, Carrive, &Waite, 2006), while nonshivering
thermogenesis is modulated by gastric stretching (Petervari, Garami,
Pakai, & Szekely, 2005), the level of intraportal glucose (Sakaguchi &
Yamazaki, 1988), and the osmolarity of the content in different parts
of the gastrointestinal tract (Boschmann et al., 2007; Osaka,
Kobayashi, & Inoue, 2002). All of the abovementioned reflexes seem il-
logical – but only until we study them, find the conditions under which
they are expressed, or just start thinking about them. For example, the
concentration of glucose in the portal blood, aswell as gastric stretching,
can be viewed as indices of energy intake, whereas nonshivering ther-
mogenesis is a major mechanism of energy expenditure in rodents; it
should not be a surprise that the latter is modulated by the former.
What could be the biological significance of the unusual TRPV1-
mediated reflexes that link pH and Tb? Because polymodal TRPV1 an-
tagonists induce robust hyperthermia in different species (Fig. 2), it is
probably related to some basic physiological interactions. Initially
(Steiner et al., 2007), we thought that interactions between the feeding
status, gastrointestinal pH, and Tb were involved. However, in view of
our recent results showing that the hyperthermic response to TRPV1
antagonists is affected neither by vagotomy (A. Garami, A. A. Steiner,
and A. A. Romanovsky, unpublished observations) nor by the transec-
tion of the greater splanchnic nerves (A. Garami and A. A. Romanovsky,
unpublished observations), we dismissed the visceral location of the
TRPV1 channels of interest and the entire “gastrointestinal” scenario
(Garami, Pakai, et al., 2018).
Instead,we propose that interactions between the acid-base homeo-
stasis, Tb, and physical activity can be relevant. Strenuous physical activ-
ity is well-known to cause metabolic acidosis, including marked
acidemia (Robergs, Ghiasvand, & Parker, 2004), and it increases
deep Tb and often peripheral temperatures. Based on the tight
co-expression of TRPV1 with acid-sensing ion channel-3 on
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that TRPV1 channels at this locationmay function as sensors for reflexes
triggered by the acidic environment and elevated temperature of work-
ingmuscles (Molliver et al., 2005). In those situations,when physical ac-
tivity is especially strenuous (e.g., when an animal is running for life
from a predator), Tbs can reach extremely high values. In a study by
Taylor and Lyman (1972), an abdominal temperature of N 47°C was re-
corded in a running gazelle. By the same token, high Tbs (whether shell
or core) inhibit physical performance (Cheung & Sleivert, 2004; Nybo,
Rasmussen, & Sawka, 2014; Schlader, Simmons, Stannard, & Mundel,
2011). Hence, a negative-feedback cycle is formed: an animal has to
run as fast as it can to survive➔ Tbs increase➔ the capability to run de-
creases. Would it not be highly beneficial to counteract the develop-
ment of hyperthermia by inhibiting cold-defense responses
(thermoregulatory heat conservation and heat production), thus
cancelling the performance-inhibiting feedback? We think it
would, and the TRPV1-mediated acido-antithermogenic and acido-
antivasoconstrictor reflexes discussed herein may do just that. When
an animal runs, its internal environment acidifies, and the low pH, via
TRPV1 channels (perhaps in the massive trunk muscles that are rich
with slow-twitch, type-1 muscle fibers and are involved in breathing),
inhibits cold defenses, thus preventing a further rise in Tb or bringing
it down. This speculative line of thought has already found support in
the studies showing that acute administration of CAP causes sympa-
thetic activation and increases exercise endurance in rats and mice
(Kim, Kawada, Ishihara, Inoue, & Fushiki, 1997; Oh, Oh, & Ohta, 2003).
Furthermore, Luo et al. (2012) have shown that TRPV1 activation by
chronic dietary CAP or transgenic TRPV1 overexpression also increases
exercise endurance in mice, and that this effect of CAP does not occur
in TRPV1-decifient mice. The concept presented here can be tested fur-
ther by blocking TRPV1-mediated reflexes in exercising animals.
At the first glance, the proposed scenario is difficult to reconcile with
the fact that lactic acid is a potent inhibitor (not activator) of TRPV1 (de
la Roche et al., 2016), whereas acidosis during physical activity is ac-
companied by massive production of lactate (Bangsbo, Madsen, Kiens,
& Richter, 1996) and, for a long time, was known as “lactic acidosis.” It
was believed that the increased production of lactic acid causes the re-
lease of protons and the formation of the acid salt sodium lactate, even-
tually exceeding the cellular buffering capacity and resulting in proton
accumulation and a pH decrease. As explained by Robergs et al.
(2004), the lactic acidosis concept has been disproved. While lactate
production coincides with metabolic acidosis in strenuous exercise, it
retards – not causes – it. In intense physical work, nonmitochondrial
ATP from glycolysis is used heavily to fuel muscle contraction, thus re-
leasing protons and causing acidosis.While extracellular lactate inhibits
TRPV1, at least in vitro (de la Roche et al., 2016), the channel is gated
open by extracellular protons (pH b 6), and milder acidosis (pH be-
tween 6 and 7) sensitizes it (reviewed by Holzer, 2009). The critical im-
portance of TRPV1 in acid-sensing has been also demonstrated in vivo –
using mice genetically deficient in TRPV1 (Caterina et al., 2000; Leffler,
Monter, & Koltzenburg, 2006).3. The hyperthermic effect of TRPV1 antagonists in human clinical
trials
3.1. Phenomenology: effects of TRPV1 antagonists on Tb in humans
As of today, a relatively large number of TRPV1 antagonists has al-
ready been tested in humans (Table 3). Besides healthy adult volun-
teers, patients with a variety of conditions and symptoms were
studied, often involving pain and inflammation (e.g., dental or neuro-
pathic pain, arthritis, or dermatitis), but also itching, coughing, and
chronic pulmonary obstruction. As part of safety assessment, deep Tb
was measured in several trials, and it is now well-known that many
TRPV1 antagonists had adverse effects on Tb in humans (Gavva et al.,2008; Krarup et al., 2011; Lee et al., 2017; Manitpisitkul et al., 2015;
Rowbotham et al., 2011).
As in laboratory animals (see 2.1), the thermoregulatory effects of
TRPV1 antagonists in humans are diverse (Fig. 9). In one of the first
human trials, AMG 517 caused marked hyperthermia with deep Tb ex-
ceeding 40°C (Gavva et al., 2008), which led to a premature termination
of the trial. A dose-dependent (and, at higher doses, pronounced: 0.8-
1.4°C) Tb rise was also observed in human trials with ABT-102 and
V116517 (Fig. 9A and 9B, respectively), as well as with XEN-D0501
(Round, Priestley, & Robinson, 2011), while AZD1386 caused a milder
(0.4°C) elevation in Tb (Fig. 9C). Another TRPV1 antagonist, SB-
705498, had no thermal effect in humans, even at doses as high as
600 mg p.o. (Fig. 9D), whereas the mode-selective antagonist
NEO6860 seemed to cause a small (0.2°C) decrease in deep Tb
(Fig. 9E). As in laboratory animals, the thermal effects of TRPV1 antago-
nists in humans show no obvious association with the antagonist’s
chemical structure, thus suggesting an on-target action.
Because TRPV1 remains a promising therapeutic target in many
human diseases and conditions (Brito, Sheth, Mukherjea, Rybak, &
Ramkumar, 2014; Feketa & Marrelli, 2015; Gram, Holst, & Szallasi,
2017; Nilius &Appendino, 2013), it is important to understandwhat de-
termines the thermoregulatory effects of TRPV1 antagonists in our own
species. We already know that some TRPV1 antagonists, e.g., CPZ and
JYL1421, affect thermoregulation in a species-specific manner (see
Section 2.1 above). We also know that at least some TRPV1 antagonists
affect the TRPV1 channel in a species-specific manner as well and,
hence, have different activation-mode pharmacological profiles against
the TRPV1 channel in different species. A famous example is the TRPV1
antagonist AMG8562, whichwas the first one reported to cause analge-
sia without hyperthermia in rats (Lehto et al., 2008). It is thought to
cause no hyperthermia in this species, because it does not inhibit proton
activation of rTRPV1. However, if this assumption is true, the success of
AMG8562 in causing hyperthermia-free analgesia in rats cannot be
reproduced in humans – this antagonist is a potent inhibitor of all
modes of activation of hTRPV1, including the proton mode (Lehto
et al., 2008). Furthermore, the regulation of thermoregulatory responses
in rats and humans is not likely to be identical; at the very least, rats do
not sweat, whereas humans do not use tail-skin vasodilation or thermo-
regulatory salivation, and neither do humans rely on nonshivering ther-
mogenesis in brown fat to the same extent as rats do (Romanovsky,
2018). Being several hundred times heavier than rats, humans take ad-
vantage of substantial thermal inertia and, accordingly, do not face the
problem of readily losing the constancy of Tb (homeothermia) in view
of environmental perturbations, at least not to the same extent as
small rodents do. Consequently, peripheral thermal signals (including
thosemediated by TRPV1) are expected to play a smaller role in humans
than in rodents (Romanovsky, 2014, 2018).
Last but not least, TRPV1 has different sensitivity to both tempera-
ture and chemical ligands in different species. For example, a TRPV1 iso-
form found in vampire bats is activated by temperatures as low as 30°C,
which presumablymakes TRPV1 a radiant-heat sensor for the detection
of warm-blooded prey (Gracheva et al., 2011). On the other extreme,
Bactrian camels express a TRPV1 ortholog that is not activated by tem-
perature as high as 46°C (Laursen, Schneider, Merriman, Bagriantsev,
& Gracheva, 2016), which, we think, is a genetic adaptation to high sur-
face temperatures in camels’ habitat during summer. Another dramatic
example refers to TRPV1 sensitivity to CAP. Avian TRPV1 is not sensitive
to CAP (Nagy & Rang, 2000), which allows birds to feed on spicy, pun-
gent, CAP-rich fruits such as hot chili peppers. In contrast, most mam-
mals, including mice (Garami et al., 2011), do not consume hot chili.
In fact, CAP-containing repellants are used to protect crops from brows-
ing by many species of mammalian pests (Romanovsky, 2015). In each
of these examples, a pharmacological blockade of TRPV1 would have a
distinct effect.
Based on the above, it is quite possible that TRPV1 antagonists cause
their thermoregulatory effect somewhat differently in humans than in
Table 3
Characteristics of clinical studies of TRPV1 antagonists
Compound (company) Patient or volunteer population Thermometry
site
Thermal effect ClinicalTrials.gov
identifier
Reference(s)
ABT-102 (Abbott) Healthy male and female
volunteers, 18-55 years
Oral Increase in Tb NCT00854659 Rowbotham et al.,
2011
ABT-102 (Abbott) Healthy volunteers Oral or
abdominal
Increase in Tb Not reported Othman et al., 2013
ABT-102 (Abbott) Healthy male volunteers, 18-60
years
Aural Dose-dependent increase in Tb Not reported Schaffler et al., 2013
AMG 517 (Amgen) Patients with pain due to molar
extraction
Oral and
tympanic
Plasma concentration-dependent
increase in Tb
Not reported Gavva et al., 2008
AZD1386 (AstraZeneca) Patients with pain due to lower
“wisdom tooth” extraction
Tb not measured Tb not measured NCT00672646 ClinicalTrials.gov
AZD1386 (AstraZeneca) Healthy volunteers Tb not measured Tb not measured NCT00692146 ClinicalTrials.gov
AZD1386 (AstraZeneca) Patients with post-traumatic or
postherpetic neuralgia
Tb not measured Tb not measured NCT00976534 ClinicalTrials.gov
AZD1386 (AstraZeneca) Patients with pain due to third
molar extraction
Oral Increase in Tb Not reported Quiding et al., 2013
AZD1386 (AstraZeneca) Patients with knee osteoarthritis Tb not measured Tb not measured NCT00878501 Miller, Bjornsson,
Svensson, & Karlsten,
2014
AZD1386 (AstraZeneca) Healthy male volunteers Not reported Dose-dependent increase in Tb NCT00711048 Krarup et al., 2011
AZD1386 (AstraZeneca) Patients with reflux disease
responsive to proton-pump
inhibitors
Not reported Increase in maximum Tb NCT01019928 Krarup et al., 2013
DWP05195 (Daewoong) Patients with postherpetic neuralgia Tb not measured Tb not measured NCT01557010 ClinicalTrials.gov
DWP05195 (Daewoong) Healthy male volunteers Not reported Dose-dependent increase in Tb
(tendency)
NCT00969787 (single
dose) NCT01094834
(multiple doses)
Lee et al., 2017
GRC-6211 (Glenmark, Eli
Lilly)
Patients with osteoarthritic pain,
incontinence, or neuropathic pain
Tb not measured Tb not measured Not reported Myers, 2008
JNJ-38893777 (Johnson &
Johnson)
Healthy male volunteers Oral Small increase in Tb Not reported Manitpisitkul et al.,
2015
JNJ-39439335 (Johnson &
Johnson)
Healthy male volunteers Tb not measured Tb not measured NCT01006304 ClinicalTrials.gov
JNJ-39439335 (Johnson &
Johnson)
Healthy male volunteers Oral Small increase in Tb Not reported Manitpisitkul et al.,
2016
JNJ-39439335 (Johnson &
Johnson)
Healthy male volunteers Oral No clinically meaningful increase
in Tb
Not reported Manitpisitkul,
Shalayda, Russel,
Sanga, Solanki, et al.,
2018
JNJ-39439335 (Johnson &
Johnson)
Healthy male volunteers (Part 1);
male and female patients with knee
osteoarthritis (Part 2)
Oral Plasma
concentration-independent
increase in Tb
Not reported Manitpisitkul, Flores,
et al., 2018
JNJ-39439335 (Johnson &
Johnson)
Healthy male volunteers Oral Small increase in Tb Not reported Manitpisitkul,
Shalayda, Russel,
Sanga, Williams, et al.,
2018
JNJ-39439335 (Johnson &
Johnson)
Patients with knee osteoarthritis Not reported Tb increased in one patient (of 33
patients)
Not reported Mayorga et al., 2017
MK-2295, or NGD-8243
(Merck)
Patients with postoperative dental
pain
Tb not measured Tb not measured NCT00387140 ClinicalTrials.gov
MR-1817 (Mochida) Healthy adult volunteers Tb not measured Tb not measured NCT00960180 ClinicalTrials.gov
NEO6860 (NEOMED,
Convance)
Healthy male volunteers Gastrointestinal
(ingestible
transmitter)
No clinically significant change in
Tb
NCT02337543 Brown et al., 2017
NEO6860 (NEOMED) Adult patients with pain due to knee
osteoarthritis
Oral No increase of more than 1°C in Tb NCT02712957 Arsenault et al., 2018
PAC-14028, or asivatrep
(Amorepacific)
Patients with dermal pruritus Tb not measured Tb not measured NCT02052531 ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific)
Patients with dermal pruritus Tb not measured Tb not measured NCT02565134 ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific)
Patients with
erythema-telangiectatic or
papulopustular rosacea
Tb not measured Tb not measured NCT02052999 ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific)
Patients with mild-to-moderate
atopic dermatitis
Tb not measured Tb not measured NCT02757729
NCT02583022
NCT02965118
ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific)
Patients with mild-to-moderate
seborrheic dermatitis of the face
Tb not measured Tb not measured NCT02749383 ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific, Seoul
National University
Hospital)
Healthy male volunteers Tb not measured Tb not measured NCT02309008 ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific)
Healthy male volunteers Tb not measured Tb not measured NCT01264224 ClinicalTrials.gov
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Table 3 (continued)
Compound (company) Patient or volunteer population Thermometry
site
Thermal effect ClinicalTrials.gov
identifier
Reference(s)
PAC-14028, or asivatrep
(Amorepacific)
Healthy adult volunteers Tb not measured Tb not measured NCT01638117 ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific)
Patients with rosacea Tb not measured Tb not measured NCT02583009 ClinicalTrials.gov
PAC-14028, or asivatrep
(Amorepacific)
Pediatric patients with atopic
dermatitis
Tb not measured Tb not measured NCT02748993 ClinicalTrials.gov
PHE-377 (PharmEste) Patients with neuropathic pain Tb not measured Tb not measured Not reported Evans, 2011
SB-705498
(GlaxoSmith-Kline)
Patients with migraine Tb not measured Tb not measured NCT00269022 ClinicalTrials.gov
SB-705498
(GlaxoSmith-Kline)
Patients with third molar extraction Tympanic Maximal change in Tb from
baseline was 0.8 ± 0.5°C at
1,000 mg (baseline not reported)
NCT00281684 ClinicalTrials.gov
SB-705498
(GlaxoSmith-Kline)
Healthy adult volunteers Tympanic Not reported NCT01476098 (oral) ClinicalTrials.gov
SB-705498
(GlaxoSmith-Kline)
Healthy adult volunteers Tb not measured Tb not measured NCT01673529 (topical) ClinicalTrials.gov
SB-705498
(GlaxoSmith-Kline)
Patients with rectal pain Tb not measured Tb not measured NCT00461682 ClinicalTrials.gov
SB-705498
(GlaxoSmith-Kline)
Healthy adult volunteers Tb not measured Tb not measured Not reported Chizh et al., 2007
SB-705498
(GlaxoSmith-Kline)
Patients with refractory chronic
cough
Tympanic No change in Tb Not reported Khalid et al., 2014
SB-705498
(GlaxoSmith-Kline)
Patients with seasonal allergic
rhinitis
Oral No change in Tb NCT01424397 Bareille et al., 2013
SYL-1001 (Sylentis) Patients with ocular pain due to
dry-eye syndrome
Tb not measured Tb not measured NCT01776658
NCT01438281
NCT02455999
Benitez-Del-Castillo
et al., 2016
V116517 (Purdue) Subjects with moderate-to-severe
pain due to knee osteoarthritis
Tb not measured Tb not measured NCT01688934 ClinicalTrials.gov
V116517 (Purdue) Patients with moderate-to-severe
postherpetic neuralgia
Tb not measured Tb not measured NCT01688947 ClinicalTrials.gov
V116517 (Purdue) Healthy male volunteers Oral No change in Tb NCT02695745 Arendt-Nielsen et al.,
2016
XEN-D0501 (Xention, Ario) Patients with chronic idiopathic
cough
Tb not measured Tb not measured NCT02233699 ClinicalTrials.gov
XEN-D0501 (Xention, Ario) Patients with refractory chronic
cough
Not reported Not reported Not reported Belvisi et al., 2017
XEN-D0501 (Xention) Healthy male (Part 1) or male and
female (Part 2) volunteers
Aural Dose-dependent increase in Tb Not reported Round et al., 2011
XEN-D0501 (Xention, Ario) Patients with chronic obstructive
pulmonary disease
Tb not measured Tb not measured NCT02233686 Smith et al., 2017
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hTRPV1 activation to the thermoregulatory effect of TRPV1 antagonists
in humans. By conducting the mathematical analyses presented below,
we intended to fill this void.
3.2. Mathematical modeling: which modes of hTRPV1 activation contribute
to the hyperthermic response in humans?
For the present work, we identified 87 published reports on human
clinical trials of TRPV1 antagonists, of which 18 trials involved recording
somemeasure of deep (core) Tb (Fig. S1). Using the sets of inclusion and
exclusion criteria (Tables S1 and S2), we were able to select five studies
for a mathematical-modeling analysis, and also for meta-analysis (see
Section 3.3. below). The full set of data used for modeling analysis is
shown in Table S3. Themodel, which is based on the one we developed
earlier (Garami et al., 2010), is described in detail in Supplementary
Methods.
The modeling analysis has found that the hyperthermic effect of
TRPV1 antagonists in humans is the most sensitive to the extent of
hTRPV1 blockade in the proton activation mode. The sensitivity coeffi-
cient of the hyperthermic response to potency changes in the proton
mode (mean ± SE) is 1.37 ± 0.00 (P = 2.48 × 10-39). In this respect,
the hyperthermic response to TRPV1 antagonists in humans is similar
to that in rats: in both species, potent blockers of proton activation
cause an increase in Tb (Fig. 10). While preparing our recent study
(Garami, Pakai, et al., 2018), we already had the information about theimportance of the proton activationmode, based on preliminary results
of our modeling analysis presented here, and we used these results to
explain the phenomenon that was not well understood. It was reported
that the TRPV1 antagonist V116517 potently blocked rTRPV1 activation
by protons and caused hyperthermia in rats (Tafesse et al., 2014), but
yet it did not cause hyperthermia in a human clinical trial, while po-
tently blocking hTRPV1 activation by protons (Arendt-Nielsen et al.,
2016). We proposed (Garami, Pakai, et al., 2018) that this discrepancy
could be explained by the use of subthreshold (for causing hyperther-
mia) doses of V116517 in that particular trial, and that V116517 is an in-
trinsically hyperthermic (not neutral) compound. The data presented in
the present work (Fig. 9B) show that our hypothesis is correct.
The present analysis has also found that, differently from the hyper-
thermic response in rats (which is insensitive to potency changes in the
heat activationmode), the response in humans is highly sensitive to the
antagonist’s potency in the heat mode. For the human response, the
sensitivity coefficient to potency changes in the heat mode is 1.09 ±
0.00 (P= 1.92 × 10-39). As for the CAP mode of activation, blocking it
is not important for the hyperthermic response in either rats or humans.
In humans, the response sensitivity to potency changes in the CAPmode
is negative and six times lower in magnitude than the sensitivity in
the proton activation mode. The sensitivity coefficient of the human
response to potency changes in the CAP mode is -0.23 ± 0.00 (P =
4.71 × 10-38).
In addition to the set ofmean sensitivity coefficients listed above and
illustrated in Fig. 10, we have also found the best-fitted set of sensitivity
Fig. 9. Deep Tb responses of humans to TRPV1 antagonists vary from high hyperthermia to low hyperthermia, no effect, or hypothermia. A) Effect of ABT-102 (2, 6, and 30 mg/kg, p.o.) or
placebo on oral temperature. B) Effect of V116517 (30, 100, and 1,000mg/kg, p.o.) or placebo on oral temperature. C) Effect of AZD1386 (95mg/kg, p.o.) or placebo on oral temperature.
D) Effect of SB-705498 (600 mg/kg, p.o.) or placebo on oral temperature. E) Effect of NEO6860 (500mg/kg, p.o.) or placebo on oral temperature. Plotted for this work based on data from
Othman et al. (2013) (A), Arendt-Nielsen et al. (2016) (see also Table S6) (B), Quiding et al. (2013) (C), Khalid et al. (2014) (D), and Arsenault et al. (2018) (E).
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randomly generated parameters; see Mathematical model description,
Supplementary Information). The best-fitted set includes the following
sensitivity coefficient values: -0.21 (CAP mode), 1.25 (proton mode),
and 1.00 (heat mode). With this set, the model accounts for a maximal
share of thehyperthermic response variation: 83% (r2=0.83). Thebest-
fitted set complements the mean values in characterizing how the po-
tency in each activation mode affects the hyperthermic response to
TRPV1 antagonists in humans.
In addition to the high value of r2, the high quality of data fitting in
ourmodel is demonstrated by the lowvalues of the so-called “mismatch
errors”, i.e., the differences between the hyperthermic response values
measured in clinical trials for the 16 antagonist doses used in this anal-
ysis (Table S3) and the corresponding response values predicted by our
model. In our current analysis, the mismatch error varies from -0.3 to
0.4°C; the quadratic mean is 0.2°C.
The more complex nature of the hyperthermic response to TRPV1
antagonists in humans, as compared to that in rats (dependence on
two activationmodes vs. one), is also evident from how varying the an-
tagonist potency in different activation modes contributes to the statis-
tical variance of the human hyperthermic response (Fig. 10). In rats, N
81% of the statistical variance of the hyperthermic response is deter-
mined by the proton mode; the contributions of both the heat mode
and theCAPmode are negligible (~1% each); and the contribution of fac-
tors unaccounted for by our model is 16%. In humans, these contribu-
tions are: 35% for the proton mode, 37% for the heat mode, 10% for the
CAP mode, and 17% for unaccounted factors.Themainfindingof our analysis is that the hyperthermic response to
TRPV1 antagonists depends on the activation-mode TRPV1 pharmacol-
ogy differently (and in a more complex fashion) in the human than in
the rat. In rats, of the three modes studied (CAP, proton, and heat),
only theprotonmodematters: thehyperthermic response is highly sen-
sitive to potency changes in this mode and is totally insensitive to po-
tency changes in the CAP or heat mode. Accordingly, only potent
blockers of rTRPV1 activation by protons cause hyperthermia in rats.
In humans, the hyperthermic response is highly sensitive to potency
changes in the proton mode of hTRPV1 activation as well. But it is also
sensitive, almost to the same extent, to potency changes in the heat
mode. Hence, perhaps the most interesting and somewhat unexpected
conclusion from our analysis is that TRPV1 plays different roles in ther-
moregulation in humans, as compared to rats. In rats, it mediates the
tonic suppression of thermogenesis and skin vasoconstriction by pro-
tons (or proton-like stimuli) in the abdomen, perhaps in trunkmuscles;
it does not serve as a thermosensor to the thermoregulation system in
this species, or at least not in young male adults. In humans, TRPV1
also seems to mediate the effect of acidity on thermoregulation, but, in
addition to this, it is likely to play a role of a true thermal sensor for
the thermoregulation system – detecting Tbs to drive thermoeffector re-
sponses. Our analysis suggests that, in order to be thermally neutral in
humans, a TRPV1 antagonist should have low potency in both tempera-
ture and proton activation modes of hTRPV1.
Ourmodel also predicts that the strongest hyperthermic response in
humans is induced by TRPV1 antagonists that are highly potent inhibi-
tors of hTRPV1 activation by both protons and heat. This prediction is
Fig. 10. Contribution of different modes of TRPV1 activation to the development of TRPV1
antagonist-induced hyperthermia in rats (A, B) and humans (C, D). TRPV1 antagonists
differentially affect TRPV1 activation by CAP, protons, and heat; some TRPV1 antagonists
cause the hyperthermic response. The sensitivity of the hyperthermic response to the
antagonist potency in each of the three activation modes is presented as bars (mean ±
standard error) for rats (A) and humans (C). While the hyperthermic response to TRPV1
antagonists in rats depends solely on the antagonist’s potency to block TRPV1 activation
by protons, the hyperthermic response in humans depends on the antagonist’s
potencies in both proton and heat modes. The pie charts depict the relative
contributions of each mode (as well as of the factors unaccounted for by the model) to
the statistical variance of the hyperthermic response in rats (B) and humans (D). Graphs
are plotted from data reported by Garami et al. (2010) (A, B) or derived from the
present mathematical analysis (C, D).
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(2008). We could not use the Gavva et al. (2008) data in our analysis
(Table S2), because the published report contained only the maximal
values of Tb over a period of time (instead of the exact values at different
time points). However, from the maximal Tb data presented, it is clear
that AMG 517 causes marked hyperthermia in humans already at the
very low dose of 2 mg (~5 μmol). AMG 517 is a highly potent blocker
of hTRPV1 activation by both protons and heat; the corresponding IC50
values are 0.6 and 1.3 nM, respectively [Table S2; also see Gavva,
Bannon, Surapaneni, et al. (2007)].
Furthermore, Tb data reported for most of the TRPV1 antagonists
with a known pharmacological profile against hTRPV1 seem to be com-
patiblewith ourmodel results (Arsenault et al., 2018; Gavva et al., 2008;
Othman, Nothaft, Awni, & Dutta, 2013; Quiding et al., 2013; Rowbotham
et al., 2011). SB-705498 may be an exception, as this compound blocks
all three activation modes of hTRPV1 with high (3-6 nM) potency
(Gunthorpe et al., 2007), and yet, in the trial reported by Khalid et al.
(2014), a high dose of this compound (600 mg, p.o.) failed to increase
deep Tb (Fig. 9D). However, the TRPV1 channel occupancy in that trial
(based on the peak plasma SB-705498 concentration) was only 45%,
thus suggesting that the dose usedmight have been insufficient for trig-
gering on-target effects, including hyperthermia.
While the modeling analysis presented here enables us to make
unique conclusions about the relationship between the activation-
mode pharmacological profiles of TRPV1 antagonists and their thermaleffects in humans, some caution should be exercised when these con-
clusions are interpreted or applied.
First, themodel processed pharmacological profiles obtained against
hTRPV1 in vitro and thermal responses recorded in humans in vivo, with
measurements performed by different groups and by different method-
ologies. We do not knowwhether the channel behaves similarly in vitro
and in vivo. We also ignore any pharmacokinetics-related differences
between different compounds.
A less obvious, but perhaps very important, reason for caution is that
themodel assumes that there are only threemodes of TRPV1 activation,
and that they are independent of each other. In reality, however, the
TRPV1 channel can be activated not only by CAP (and other vanilloids
and some endocannabinoids), protons (acidic pH), and heat, but also
by the myriad of other endogenous and exogenous ligands, including
– just to give some examples – divalent (e.g., Ni2+) and trivalent (e.g.,
Gd3+) cations, polyamines, basic pH, eicosanoids, phospholipids, and
terpenoids (for review, see Calixto, Kassuya, Andre, & Ferreira, 2005;
Nilius & Szallasi, 2014). In fact, TRPV1 is known as the polymodal recep-
tor par excellence (Holzer, 2009). Furthermore, there is certainly a
crosstalk between different modes of TRPV1 activation (Blumberg
et al., 2011), e.g., mild acidosis sensitizes TRPV1 to both CAP and heat
(reviewed by Holzer, 2009). The interdependence of different modes
of TRPV1 activation clouds any interpretations of our modeling results.
Last but not least, the inordinate promiscuity of the TRPV1 channel
makes it utterly sensitive to its environment. Accordingly, the channel
is likely to play different physiological roles with changes in conditions,
even in the same species. Consequently, effects of TRPV1 antagonists
can also be expected to differ under different conditions. In the study
by Gram et al. (2019) in Zucker obese rats, the TRPV1 antagonist BCTC
improved insulin secretion at a young age of 6 months, but did not
have this effect at a more mature age of 9 months. In our study
(Wanner et al., 2012), the hyperthermic effect of AMG 517 in aged (44
weeks) mice was very similar to that in young (12 weeks) mice, but
the effect of the antagonist on systemic inflammation changed with
aging from anti-inflammatory to proinflammatory. Furthermore, the ef-
fect of AMG 517 on mortality of systemic inflammation in aged mice
depended onwhether the inflammation was septic (induced by colonic
ligation and puncture) or aseptic (induced by a high dose of bacterial
lipopolysaccharide).
A sex-dependent effect of the TRPV1 antagonist ABT-116 on locomo-
tor activity was found in dogs; this compound produced a stronger ef-
fect in males than in females (Malek et al., 2012). Sex-dependent
differences in the effects of CPZ on audiogenic seizures in rats (Cho,
Vaca,Miranda, &N'Gouemo, 2018) and on the urethral response to nox-
ious stimulation inmice (Yoshiyama, Araki, Kobayashi, Zakoji, & Takeda,
2010) have also been reported. These differences may be due to the
demonstrated effects of ovariectomy, pregnancy, and sex hormones
(viz., progesterone, estradiol, and prolactin) on the expression and ac-
tivity of TRPV1 in mice and rats (Diogenes et al., 2006; Ortiz-Renteria
et al., 2018; Payrits et al., 2017; Wu et al., 2010). Estradiol has also
been shown to upregulate TRPV1 at the mRNA level in human sensory
neurons derived from embryonic stem cells (Greaves, Grieve, Horne, &
Saunders, 2014).
Some thermoregulatory effects of TRPV1 antagonists may also be
sex-dependent. Based on our experiments with AMG0347 in male rats
(Steiner et al., 2007), we concluded that TRPV1 antagonists readily re-
cruit autonomic thermoeffectors in the hyperthermic response, but do
not use behavioral regulation (we are now revisiting the latter conclu-
sion in a new study). Based on our experiments with multiple TRPV1
antagonists in male rats (Garami et al., 2010; Steiner et al., 2007), we
concluded that blocking thermal signals does not affect thermoregula-
tion. To our surprise, our recent experiments have shown that several
TRPV1 antagonists affect behavioral thermoregulation in female rats,
possibly by blocking thermal signals (Romanovsky, 2019). Clearly,
more studies are needed, and any results obtained with TRPV1 antago-
nists should be generalizedwith great care.Without having amodel of a
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this phenomenon in a systematic way, but one should always be
ready to change the model as new experimental data arrive.
3.3. Human clinical trials: meta-analysis
In addition to mathematical modeling, we also conducted a meta-
analysis of the data reported in the identified articles, using standard
meta-analysis tools (see Supplementary Methods), in accordance with
the guidelines of the Preferred Reporting Items for Systematic Reviews
(Table S4) and Meta-Analysis Protocols (Moher, Liberati, Tetzlaff, &
Altman, 2009). This analysis was registered with PROSPERO (CRD
42018095220).
We included the studies that reported deep Tb values in both TRPV1
antagonist-treated and placebo groups at least at two time points: (i) at
or shortly before the drug (or placebo) administration and (ii) at 3 h
after the timeof administration (Table S1). Studies forwhich all the nec-
essary information could not be obtained were excluded from the anal-
ysis (Table S2). In certain cases, we had to make limited assumptions or
simplifications, as explained in Table S5. The demographic profiles of
the studies are outlined in Table S6. For each included study, we calcu-
lated the change in deep Tb as a difference between the Tb values at
3 h after the drug (placebo) administration vs. at the time of administra-
tion (0h); this is the Tb change thatwasused in themodeling analysis as
the valueH of the hyperthermic response.We then calculated the differ-
ence between the Tb changes induced by a drug and those induced by
placebo (difference in means); we considered the latter difference to
represent the thermal effect of the drug in our meta-analysis. For all
doses, the differences inmeanswere standardized (based on variances)
to obtain standardized differences in means (SDMs). The SDMs with
95% confidence intervals (CIs) were used as primary measures of effect
size and are presented as a “forest plot” (Fig. 11). We considered each
TRPV1 antagonist to be either mode-nonselective (ABT-102, AZD1386,
and V116517) or mode-selective (NEO6860). To characterize the non-
selective group, SDMs for the corresponding antagonists wereweighted
based on sample size and inversed variance.
All three antagonists in themode-nonselective group caused hyper-
thermia, which was dose-dependent for those compounds that were
administered at multiple doses, viz., ABT-102 and V116517 (Fig. 11).Fig. 11. Forest plot of the thermal effects of TRPV1 antagonists. For each antagonist dose, an SDM
and are shown in the figure with a square and a horizontal bar, respectively. The area of the sq
weighted mean SDM for the mode-nonselective group; the vertical diagonal of the rhombus
refer to mode-nonselective TRPV1 antagonists; the green square and bar refer to the selectiveThe highest hyperthermic effect (SDM: 2.5; CI: 1.4-3.5) occurred in
the group treated with the 86 μmol dose of ABT-102. The mean thermal
effect of all doses of all mode-nonselective TRPV1 antagonists in the an-
alyzed clinical trials was an SDMof 1.2 (CI: 0.9-1.6; P b 0.001). These re-
sults of meta-analysis agree with ourmathematical-modeling results in
that the blockade of the proton and heat activation modes of the
hTRPV1 channel, as typically observed for polymodal TRPV1 antago-
nists, results in hyperthermia.
NEO6860, the only mode-selective TRPV1 antagonist that we were
able to include in our analysis, did not cause hyperthermia at the dose
used (1.2 mmol) but, instead, decreased the deep Tb (SDM: -0.7; CI:
-0.3 to -1.1; P b 0.001). The lack of hyperthermia in response to
NEO6860 agrees with our mathematical model, since this compound
blocks neither proton nor heat activation of hTRPV1. The hypothermic
effect of NEO6860 could be explained by the reported partial agonistic
activity of this compound against hTRPV1 (Arsenault et al., 2018).
TRPV1 agonists are well-known to cause hypothermia (Romanovsky
et al., 2009; Szolcsanyi, 2015). TRPV1 antagonistswith partial TRPV1 ag-
onistic properties, such as 5’-iodo-RTX (Blumberg et al., 2011; Dogan
et al., 2004; Shimizu, Iida, Horiuchi, & Caterina, 2005) or AbbVie’s Com-
pound 3 (Gomtsyan et al., 2015), also cause hypothermia. As a limita-
tion of our meta-analysis, it should be mentioned that we analyzed
only one dose of a single mode-selective drug; this analysis should be
repeated as more data become available.
4. Tackling the thermal effects of TRPV1 antagonists: approaches to
drug development
4.1. Designing thermally neutral antagonists based on mode-selective
TRPV1 pharmacology
Perhaps the best solution would be to design a TRPV1 antagonist
that possesses sufficient efficacy as an analgesic (or in respect to any
other desired effects) but does not cause any of the on-target adverse ef-
fects on Tb, i.e., hypo- or especially hyperthermia. Based on the current
work, the thermal effects are likely to be minimal in humans for the
compounds that do not block hTRPV1 activation by protons and tem-
perature, even if they are still potent blockers of the channel activation
by CAP. If the proton- and heat-blocking potencies are low enough,(ameasure of the Tb response) and CIwere calculated as described in the text (section 3.3)
uare is proportional to the sample size and inversed variance. The rhombus refers to the
points at the SDM value, whereas the horizontal diagonal represents the CI. Red symbols
antagonist NEO6860.
19A. Garami et al. / Pharmacology & Therapeutics 208 (2020) 107474while the CAP-blocking potency is high enough, such a compound or bi-
ological has a chance of possessing sufficient efficacy (by potently
blocking hTRPV1 activation by vanilloids) without affecting Tb. Rational
design of therapeutics with this activation-mode profile clearly pushes
the current boundaries of molecular pharmacology. Nonetheless, there
are hints from TRPV1 mutational data that this may be possible. Early
studies of TRPV1 orthologs showed that residues in the vanilloid-
binding pocket could be mutated (Tyr511Ala and Ser512Tyr), which
would selectively disrupt the CAP sensitivity, while retaining high sen-
sitivity in the heat and proton activation modes (Jordt & Julius, 2002).
Similarly, mutations in the pore turret of murine TRPV1 can selectively
abrogate heat activation without impacting CAP activation (Cui et al.,
2012),while distinct but proximalmutations have been shown to selec-
tively disrupt proton activation (Jordt et al., 2000). More recently, ran-
dom scanning mutagenesis of rTRPV1 has identified hundreds of
specific mutations across the TRPV1 protein that retain either CAP- or
heat-selective activation – although it is unclear how these mutations
impact proton activation (Sosa-Pagan, Iversen, & Grandl, 2017). Taken
together, these data prove that TRPV1 activation involves at least
some stimuli-specific mechanismic differences. Leveraging these differ-
ences in gating-coupling modes of TRPV1 activation can potentially be
instrumental for developing therapeutics. Indeed, multiple TRPV1 an-
tagonists with various degrees of mode-selectivity (second-generation
antagonists) have been synthesized, and some even tested in humans
(vide supra).
There are two main obstacles for this approach. First, limited by the
extent of the current knowledge, rational engineering ofmode-selective
TRPV1 compounds remains at an early stage. Second, there may be an
intrinsic limit on how much the overall activation of TRPV1 can be
blocked (for therapeutic purposes) without blocking channel activation
by protons and temperature (to prevent thermoregulatory side effects).
Reflecting this inherent limitation, the reasons for failure of TRPV1 an-
tagonist clinical trials are now different than they were a decade ago.
The early trials were conducted with first-generation (mode-nonselec-
tive) antagonists, and they typically failed due to the adverse hyperther-
mic effect; the trial with AMG 517 being a well-known example (Gavva
et al., 2008). In contrast, severalmore recent trials were conductedwith
second-generation (mode-selective) TRPV1 antagonists, and some of
these trials did not demonstrate the anticipated level of analgesia; trials
of NEO6860 (Arsenault et al., 2018) being an example.
While rational engineering of TRPV1 antagonists with a desired pro-
file is maturing, less efficient tools can also be used to achieve the same
results, e.g., “random” synthesis and in-vitro pharmacological screening.
Based on publications, several thermally neutral, mode-selective TRPV1
antagonists have been (or were) considered by pharmaceutical compa-
nies for further development, including A-1165442 and A-1115760 by
Abbott Laboratories and AbbVie (Reilly et al., 2012; Voight et al.,
2014), AS1928370 (ASP8370) by Astellas Pharma (Oka et al., 2018;
Watabiki, Kiso, Kuramochi, et al., 2011; Watabiki, Kiso, Tsukamoto,
Aoki, & Matsuoka, 2011), and NEO6860 by NEOMED Institute
(Arsenault et al., 2018; Brown et al., 2017).
4.2. Using therapeutic doses that are subthreshold for the hyperthermic
response
In the section above, we discussed development of TRPV1 antago-
nists that are thermally neutral, meaning that they do not cause a ther-
mal response in the entire dose range that can be reasonably expected
to be used. However, the developers will always face conflicting de-
mands: a thermally neutral antagonist, at least according to our
model, should not block heat and proton activation of hTRPV1, whereas
in order to be an efficacious analgesic (or whatever the desired thera-
peutic effectmight be), it should potently block TRPV1 activation, some-
times in all modes. As a result, “compromise” antagonists are likely to
emerge that exhibit some antagonism in non-CAP modes of activation
at the price of causing hyperthermia at higher doses. Finding such acompromise, i.e., using potentially hyperthermic antagonists at doses
that are subthreshold for causing hyperthermia, can be viewed as a sep-
arate approach for dealing with the thermoregulatory side effects. This
approach exploits differential sensitivity of the therapeutic vs. side ef-
fects to changes in exposure; it is also known as the therapeutic
index-based approach. As evident from the literature, this approach
might have been explored by Purdue Pharma in connectionwith the de-
velopment of V116517, as discussed in section 3.2 (also see Fig. 9B).
Since in an earlier trial in humans the TRPV1 antagonist XEN-D0501
caused dose-dependent hyperthermia (Round et al., 2011), one could
speculate that the same approach may be used by the young pharma-
ceutical company Pila Pharma, which is developing XEN-D0501 for
treating obesity and diabetes (Gram et al., 2017). Pila Pharma is also
likely to be taking advantage of the approach described in the next
section.
4.3. Taking advantage of the tachyphylaxis phenomenon
Another strategy to minimize the hyperthermia is by taking advan-
tage of the fact that the hyperthermic effect of some TRPV1 antagonists
fades away with repeated administration, whereas the desired effect
(e.g., analgesic) may not undergo such an attenuation (Gavva, Bannon,
Hovland Jr., et al., 2007). The fading of the effect with repeated admin-
istration is called desensitization, or tachyphylaxis; we will use the lat-
ter term – to avoid confusion with CAP- or RTX-induced desensitization
discussed in previous sections. In different animal models it has been
shown that repeated dosing of AMG 517, AMG8163 (Gavva, Bannon,
Hovland Jr., et al., 2007) or ABT-102 (Honore et al., 2009) can favorably
shift the ratio of the desired effect (analgesia) to the adverse effect (hy-
perthermia). It is speculated that the selective modulation of some (but
not other) effects of TRPV1 antagonistswith repeated dosing can be due
to the antagonist-sensitive regulation of the subcellular distribution of
TRPV1, which can lead to relative strengthening or weakening of
TRPV1-mediated responses generated from different locations within
a cell (Johansen, Reilly, & Yost, 2006). While the exact molecular mech-
anisms of the effect-specific tachyphylaxis seen at thewhole-body level
are unknown, it is interesting that rTRPV1 desensitization in vitro (re-
vealed as reduced ion conductance) has different mechanisms when
caused by different stimuli. Whereas CAP-induced desensitization is
Ca2+- and calmodulin-dependent (Rosenbaum, Gordon-Shaag, Munari,
& Gordon, 2004) and at least partially reversible (Numazaki et al., 2003),
heat-induced desensitization is independent of either Ca2+ or calmodu-
lin and, on the experimental time scale, is irreversible (Sanchez-Moreno
et al., 2018).
Repeated administration of TRPV1 antagonists was also tested in
human clinical trials. In the trial by Amgen (Gavva et al., 2008), the hy-
perthermic response to the highest dose (10 mg) of AMG 517 (but not
to a lower dose of 2 or 5 mg) was attenuated with repeated antagonist
administration (Fig. 12A). In the trials conducted by Abbott Laborato-
ries, the hyperthermic response to any dose of ABT-102 used (1, 2, or
4 mg, twice a day) attenuated gradually with repeated dosing and
faded by day 7 [Fig. 12B; also see Rowbotham et al. (2011)]. In the
trial reported by Round et al. (2011), XEN-D0501 caused a dose-
dependent core Tb increase, which was greatest on the first day of dos-
ing but rapidly attenuated thereafter for all doses tested (1, 2.5, and 5
mg, twice a day) and, by day 14, was 0.3°C or less (as compared to the
placebo group) for all doses studied.
A priori, any pharmaceutical company that deals with a chronic con-
dition, thus requiring repeated drug administration, and works on
TRPV1 antagonists with an inherent hyperthermic activity may try to
use a tachyphylaxis protocol, whether by desire or as an added benefit
of repeated dosing. Purdue Pharma conducted clinical trials of their
TRPV1 antagonist V116517 (NCT01688934, 2012; NCT01688947,
2012). According to R. Kapil and D. J. Kyle (unpublished observations),
the company saw a rapid abatement of hyperthermia with repeated
dosing of V116517 in laboratory animals and humans alike, thus
Fig. 12. Themagnitude of the hyperthermic response to TRPV1 antagonists decreaseswith
subsequent administration in humans. A) The effect of AMG 517 (2, 5, and 10mg/kg, p.o.,
twice a day) or placebo onmaximumtympanic temperature is shown for thefirst 7 days of
treatment (days 0-6). B) The effect of ABT-102 (1, 2, and 4 mg/kg, p.o., twice a day) or
placebo on abdominal temperature is shown for the first 7 days of treatment. Plotted for
this work based on data from Gavva et al. (2008) (A) and Rowbotham et al. (2011) (B).
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Pharma, several other companies, including Amgen, Daewoong Phar-
maceutical, Pila Pharma, and Abbott Laboratories exercised (or at least
considered) this approach, as is evident from the published reports
(Gavva et al., 2008; Lee et al., 2017; Round et al., 2011; Rowbotham
et al., 2011).
4.4. Combining a TRPV1 antagonist with an antihyperthermic drug
The low-hanging fruit was picked first. Several TRP programs at
pharmaceutical companies considered combining a hyperthermic
TRPV1 antagonist with some of the most obvious choices for drugs de-
creasing Tb – conventional antipyretics. Amgen published some re-
search on this topic. Amgen’s first report (Gavva, Bannon, Hovland Jr.,
et al., 2007) described an attempt of combining the TRPV1 antagonist
AMG8163 with acetaminophen, an active constituent of Tylenol (and
of more than 500 other over-the-counter and prescription medicines
used to treat fever and pain). It appeared that acetaminophen didattenuate the hyperthermia induced by AMG8163 but only at a super
high, hypothermia-inducing dose of 300 mg/kg, which is analogous to
a 21-g bolus dose for a 70-kg human. Lower doses of acetaminophen
that are normally used to treat fever (and that do not affect Tb in afebrile
– without fever – conditions) do not diminish the hyperthermic re-
sponse to AMG8163 in rats (Gavva, Bannon, Hovland Jr., et al., 2007).
Nor do they affect the hyperthermic response to AMG517 in human pa-
tients undergoing molar extraction (Gavva et al., 2008).
These negative results should not come as a surprise, because acet-
aminophen is thought to block fever by inhibiting cyclooxygenase
(Engstrom Ruud et al., 2013), the key enzyme in the synthesizing cas-
cade of prostaglandin E2 (Ivanov & Romanovsky, 2004). While prosta-
glandin E2 is the principal mediator of fever (Garami, Steiner, &
Romanovsky, 2018), there are no data on prostaglandin involvement
in the genesis of the hyperthermic response to TRPV1 antagonists. The
noninvolvement of prostaglandin E2 would explain the resistance of
AMG8163- or AMG 517-induced hyperthermia to acetaminophen. On
the other hand, the attenuation of AMG8163-induced hyperthermia in
rats by the super high dose of acetaminophen (Gavva, Bannon,
Hovland Jr., et al., 2007) is likely to be independent of TRPV1 and has
been proposed to involve TRPA1 (Mirrasekhian et al., 2018), even
though TRPA1 does not seem to play a role in Tb regulation in rats (de
Oliveira et al., 2014). Alternatively, the hypothermic action of very
high doses of acetaminophen can be, at least partially, due to the accu-
mulation of acetaminophen metabolites, some of which exert a
TRPV1-agonistic action (Eberhardt et al., 2017; Ohashi et al., 2017;
Stueber et al., 2018).
A more fruitful approach can be combining a hyperthermic TRPV1
antagonist with a drug that blocks the sympathetic activation. Indeed,
TRPV1 antagonists increase Tb by mounting the autonomic cold-
defense responses: thermogenesis and skin vasoconstriction (Gavva
et al., 2008; Steiner et al., 2007). These responses are sympathetically-
driven not only when they are triggered by cold exposure or pyrogens
(Morrison, 2011), but alsowhen they are induced byTRPV1 antagonists,
e.g., AMG9810 (Alawi et al., 2015). The sympathetic mediation of TRPV1
antagonist-induced hyperthermia paves a way for combining a TRPV1
antagonist with a sympatholytic (sympathoplegic) drug, i.e., a drug
that opposes the downstream propagation of the neural signal in the
sympathetic nervous system. The broad class of sympatholytics exploits
a plethora of mechanisms and includes postsynaptic α- and β-
adrenoreceptor antagonists, presynaptic α2-adrenoreceptor agonists,
catecholamine synthesis inhibitors, vesicular monoamine transporter
inhibitors, and drugs with some other mechanisms of action (Stowe &
Ebert, 2013). Based on the public information (Gomtsian, 2019), the
pharmaceutical startup Synventa may be using the strategy described
in this section. Synventa proposes that the α2-adrenoceptor agonist
lofexidine can prevent the hyperthermic effect of a TRPV1 antagonist
and that using the two together will result in a thermally neutral anal-
gesic combination.4.5. Turning the adverse hyperthermia into a desired effect
Yet another approach to dealingwith the adverse effect of TRPV1 an-
tagonists on Tb would be to exploit their hyperthermic potential for a
therapeutic purpose, e.g., for counteracting hypothermia associated
with general anesthesia in surgery (Schmidt, 2017) and possibly other
types of hypothermia, especially when accompanied by pain or
hyperalgesia. Anesthesia-associated hypothermia can be dramatic in
magnitude (several degrees Celsius) and carries a significant risk of se-
rious adverse effects, including coagulopathy and blood loss, as well as
an increased propensity for wound infection (Ruetzler & Kurz, 2018).
In animalmodels (Fig. 13), TRPV1 antagonists readily prevent or reverse
anesthesia-associated hypothermia, while reducing the need for opioids
for coping with postsurgical pain (Garami et al., 2017). As evident from
the literature (Schmidt, 2017) and a published patent application
Fig. 13.AMG 517 causes hyperthermia in conscious rats but prevents hypothermia during
anesthesia –without causing hyperthermia. A) The effect of AMG 517 (1mg/kg, i.v.) or its
vehicle on colonic temperature of rats pretreated with saline (i.p.) at a subneutral Ta of
23°C. B) The effect of AMG 517 (1 mg/kg, i.v.) or its vehicle on colonic temperature of
rats pretreated with ketamine (100 mg/kg, i.p.) at a subneutral Ta of 23°C. Modified with
permission from Garami et al. (2017).
21A. Garami et al. / Pharmacology & Therapeutics 208 (2020) 107474(Patwardhan, Porreca, & Romanovsky, 2017), the strategy described in
this section is used by the pharmaceutical startup Catalina Pharma.
5. Summary and conclusions
1. In rats and other laboratory animals, TRPV1 antagonists alter the
level of Tb: most cause hyperthermia, whereas some produce hypo-
thermia, and yet others exert no effect on thermoregulation. In gen-
eral, the thermoregulatory effects of TRPV1 antagonists are dose-
dependent. For some compounds, the effects are species-specific.
Themost common effect – hyperthermia – often fadeswith repeated
dosing. Despite their diversity, all these thermoregulatory responses
are likely to reflect an on-target (TRPV1-mediated) action of TRPV1
antagonists.
2. The TRPV1 protein is a species-specific channel that can be activated
by a variety of stimuli, including (but not limited to) CAP and othervanilloids, protons (low pH), and heat. Activation of TRPV1 by differ-
ent stimuli involves at least somemechanismic differences related to
distinct portions on the channel structure and different loci of the
molecule. These activation-mode-specific differences pave the way
for developing mode-selective (mode-specific) TRPV1 antagonists.
TRPV1 antagonists that potently block all activationmodes are called
mode-nonselective (or mode-nonspecific); they represent the first
generation of TRPV1 antagonists. Second-generation (mode-selec-
tive) TRPV1 antagonists potently block the channel activation by
CAP, but exert different effects (e.g., potentiation, no effect, or low-
potency inhibition) in either the proton mode or the heat mode, or
both.
3. In young male rats, TRPV1 channels are not used as thermosensors
for the thermoregulation system: thermal (Tb) signals that are me-
diated by TRPV1 do not normally drive thermoeffector responses
in this species. Hence, blocking thermal activation by TRPV1 an-
tagonists has no thermoregulatory effect in rats. Contrary to the
widespread assumption, the mechanism of thermoregulatory
effects of TRPV1 antagonists in this species does not involve
blocking TRPV1-mediated thermosensation. Instead, TRPV1
antagonists affect thermoregulation by blocking the tonic TRPV1
activation by protons (or other ligands that share the proton acti-
vation mechanism) on sensory afferents somewhere in the trunk
(abdomen), perhaps in the muscles. The hyper- and hypothermic
responses share the same mechanism, which utilizes the acido-
antithermogenic and acido-antivasoconstrictor reflexes. When
the tonic activation of truncal TRPV1 channels is blocked (by
hyperthermic antagonists) or potentiated (by hypothermic
antagonists), the autonomic cold defenses (thermogenesis and
cutaneous vasoconstriction) become either disinhibited or
further inhibited, respectively, and either hyper- or hypothermia
occurs. This mechanism may play a vital role during strenuous
exercise by attenuating the inhibitory effect of Tb on physical
performance.
4. If onewere to design an “ideal” TRPV1 antagonist to treat pain in rats,
such a compound would belong to the second generation and be a
potent blocker of rTRPV1 activation by CAP and heat (to be an effica-
cious analgesic) but would not affect rTRPV1 activation by protons
(to be free of the adverse effects on Tb).
5. Similar to their effects in laboratory rodents, TRPV1 antagonists alter
the level of Tb in humans:most cause dose-dependent hyperthermia,
whereas some may produce hypothermia. The hyperthermic effect
often fades with repeated dosing.
6. The mathematical modeling used in the present work shows that
the hyperthermic effect of a TRPV1 antagonist in humans depends
on the compound’s potency to block channel activation not only
by protons, but also by heat. The connection between the hyper-
thermic response to TRPV1 antagonists and the heat mode of
TRPV1 activation is present only in humans, not in rats. Similar to
the hyperthermia in rats, the thermoregulatory response to a
TRPV1 antagonist in humans does not depend on the compound’s
potency to block TRPV1 activation by CAP.
7. Based on the model analysis, we speculate that the role of TRPV1
in thermoregulation differs drastically between rats and humans.
Whereas in rats TRPV1 channels modulate Tb via, most likely, pH
signals from the trunk but are not used as thermosensors by the
thermoregulation system, TRPV1 channels in humans may play
both roles. The location of TRPV1 channels that sense Tbs
(whether shell or core) to drive thermoeffector responses in
humans is unknown and can be different from the location of
the channels that are tonically activated by protons. Knowing
that the skin plays a prominent thermosensory role in all spe-
cies, at least some TRPV1 channels that mediate thermal signals
to drive thermoeffectors in humans can be speculated to be lo-
cated in the skin.
122 A. Garami et al. / Pharmacology & Therapeutics 208 (2020) 1074748. An “ideal” TRPV1 antagonist to treat pain in humans would be-
long to the second generation and be a potent blocker of
hTRPV1 activation by CAP (to be an efficacious analgesic) but
would not affect hTRPV1 activation by protons or heat (to be
free of the adverse effects on Tb). The main concern about such
an antagonist would be potentially a reduction in the level of ef-
ficacy. Such a drug would be most suited for treating pain
caused exclusively through the CAP mode of TRPV1 activation
– without any involvement of the heat and proton activation
modes of activation; it is unclear whether such pain exists
under natural conditions.
9. Our meta-analysis of the human-trial data has confirmed that the
first-generation TRPV1 antagonists cause hyperthermia in humans,
whereas the second-generation compounds may lack this effect.
0. The strategies of harnessing the thermoregulatory effects of TRPV1
antagonists in humans include: (i) creating inherently thermally
neutral compounds based onmode-selective TRPV1 pharmacology,
either by rational design or by more traditional approaches; (ii)
creating potentially hyperthermic TRPV1 antagonists but with
such profiles that would allow balancing the therapeutic effect
with the adverse hyperthermic effect by using therapeutic doses
that are subthreshold for the hyperthermia; (iii) taking advantage
of the tachyphylaxis phenomenon (fading of the hyperthermic ef-
fect with repeated dosing) – in those cases when the desired ther-
apeutic effect does not fade; (iv) combining a hyperthermic TRPV1
antagonist with an antihyperthermic drug (e.g., a sympatholytic);
and (v) turning the adverse hyperthermia into a desired effect,
e.g., by using TRPV1 antagonists to prevent anesthesia-associated
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